



Stabilis



Famotidine



Noms commerciaux

Famotidina	Chili
Famotidine	Canada, Etats Unis d'Amérique
Femidin	Inde
Gaster	Japon
Nevofam - L	Turquie
Pepdine	Maroc
Quamatel	Hongrie, Pologne, Roumanie
Ulcusan	Autriche



Stabilité des solutions

PVC		2 mg/ml	4°C		14			690
PVC		0,2 mg/ml	-20°C		28			553
PVC		0,2 mg/ml	22°C		15			215
PVC		0,2 mg/ml	25°C		15			693
PVC		0,2 mg/ml	4°C		14			553
PVC		0,2 mg/ml	4°C		63			693
PVC		2 mg/ml	4°C		14			690
PVC		0,2 mg/ml	-20°C		28			553
PVC		0,2 mg/ml	22°C		15			215
PVC		0,2 mg/ml	25°C		15			693
PVC		0,2 mg/ml	4°C		14			553
PVC		0,2 mg/ml	4°C		63			693
PVC		2 mg/ml	4°C		14			690
PP		2 mg/ml	-20°C		56			77
PP		0,2 mg/ml	22°C		15			215
PP		2 mg/ml	-20°C		56			77
PP		0,2 mg/ml	22°C		15			215

		2 mg/ml	-20°C		21			77
--	--	---------	-------	--	----	--	--	----



Stabilité en mélange

								
		1 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	4		2279
		0.1 & 2 mg/ml	25°C		Tirofiban : 25 µg/ml	4		1420
		0,08 mg/ml	23°C		Flumazenil : 0,02 mg/ml	24		187
		0.1 & 2 mg/ml	25°C		Tirofiban : 25 µg/ml	4		1420
		0,4 mg/ml	25°C		Scopolamine hydrobromide : 0,04 mg/ml Haloperidol lactate : 0,5 mg/ml Dimenhydrinate : 5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	12		2166
		0,4 mg/ml	25°C		Midazolam hydrochloride : 1 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96		2166
		0,4 mg/ml	25°C		Metoclopramide hydrochloride : 0,5 mg/ml Ketoprofene : 1,5 mg Hydromorphone hydrochloride : 10 mg/ml	96		2166
		0,4 mg/ml	4°C		Scopolamine hydrobromide : 0,04 mg/ml Haloperidol lactate : 0,5 mg/ml Dimenhydrinate : 5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	12		2166
		0,4 mg/ml	4°C		Midazolam hydrochloride : 1 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96		2166
		0,4 mg/ml	4°C		Metoclopramide hydrochloride : 0,5 mg/ml Ketorolac tromethamine : 1,5 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96		2166
		0,2 mg/ml	25°C		Vancomycin hydrochloride : 0,5 mg/ml	14		1748
		0,2 mg/ml	25°C		Cefmetazole sodium : 5 mg/ml	5		237
		0,2 mg/ml	4°C		Cefmetazole sodium : 5 mg/ml	7		237
		0,2 mg/ml	4°C		Vancomycin hydrochloride : 0,5 mg/ml	14		1748



Compatibilités

Famotidine : 2 mg/ml Aciclovir sodium : 7 mg/ml		215
Famotidine : 2 mg/ml Allopurinol sodium : 3 mg/ml		307
Famotidine : 2 mg/ml Amifostine : 10 mg/ml		3

		Famotidine Aminophylline : 2,5 mg/ml		397
		Famotidine : 2 mg/ml Aminophylline : 2.5 mg/ml		215
		Famotidine : 10 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Famotidine : 10 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Famotidine : 2 mg/ml Amphotericin B : 0.6 mg/ml		215
		Famotidine : 2 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml		921
		Famotidine Ampicillin sodium : 20 mg/ml		397
		Famotidine : 2 mg/ml Ampicillin sodium : 20 mg/ml		215
		Famotidine Ampicillin sodium - sulbactam sodium : 30 mg/ml		397
		Famotidine : 2 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Famotidine : 0.2 mg/ml Atropine sulfate : 0.1 mg/ml		398
		Famotidine : 2 mg/ml Azithromycine : 2 mg/ml		1800
		Famotidine : 2 mg/ml Aztreonam : 40 mg/ml		99
		Famotidine : 2 mg/ml Bivalirudin		3539
		Famotidine : 10 mg/ml Bivalirudin		3539
		Famotidine : 2 mg/ml Bivalirudin : 5 mg/ml		1713
		Famotidine : 0.2 mg/ml Bretylium tosilate : 4 mg/ml		398
		Famotidine Calcium gluconate : 1 mg/ml		397
		Famotidine : 2 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Famotidine Cefalotin sodium : 20 mg/ml		397
		Famotidine : 2 mg/ml Cefazolin sodium : 20 mg/ml		215
		Famotidine Cefazolin sodium : 20 mg/ml		397
		Famotidine : 4 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Famotidine : 4 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Famotidine Cefoperazone sodium : 40 mg/ml		397
		Famotidine : 2 mg/ml Cefotaxime sodium : 20 mg/ml		215

	Famotidine Cefotaxime sodium : 20 mg/ml		397
	Famotidine : 2 mg/ml Cefoxitin sodium : 20 mg/ml		215
	Famotidine Cefoxitin sodium : 20 mg/ml		397
	Famotidine : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
	Famotidine : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
	Famotidine : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Famotidine Ceftazidime : 20 mg/ml		397
	Famotidine : 2 mg/ml Ceftazidime : 20 mg/ml		215
	Famotidine Ceftizoxime sodium : 20 mg/ml		397
	Famotidine : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Famotidine : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Famotidine Ceftobiprole medocaril sodium		4650
	Famotidine : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Famotidine : 4 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	Famotidine : 4 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	Famotidine : 2 mg/ml Ceftriaxone disodium : 20 mg/ml		215
	Famotidine : 2 mg/ml Cefuroxime sodium : 20 mg/ml		215
	Famotidine Cefuroxime sodium : 15 mg/ml		397
	Famotidine : 2 mg/ml Chlorpromazine hydrochloride : 2 mg/ml		215
	Famotidine : 2 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Famotidine : 2 mg/ml Cladribine : 0.015 mg/ml		1496
	Famotidine : 2 mg/ml Cladribine : 0.5 mg/ml		1496
	Famotidine Dexamethasone sodium phosphate : 10 mg/ml		397
	Famotidine : 2 mg/ml Dexamethasone sodium phosphate : 1 mg/ml		215
	Famotidine : 2 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Famotidine Digoxin : 250 µg/ml		397

	Famotidine : 2 mg/ml Diphenhydramine hydrochloride : 2 mg/ml		215
	Famotidine : 0.2 mg/ml Dobutamine hydrochloride : 1 mg/ml		398
	Famotidine : 2 mg/ml Dobutamine hydrochloride : 40 mg/ml		215
	Famotidine : 2 mg/ml Docetaxel : 0.9 mg/ml		1754
	Famotidine : 0.2 mg/ml Dopamine hydrochloride : 1.6 mg/ml		398
	Famotidine : 2 mg/ml Dopamine hydrochloride : 1.6 mg/ml		215
	Famotidine : 2 mg/ml Doripenem : 5 mg/ml		2262
	Famotidine : 2 mg/ml Doripenem : 5 mg/ml		2262
	Famotidine : 2 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Famotidine : 2 mg/ml Droperidol : 0.4 mg/ml		215
	Famotidine : 0.2 mg/ml Enalaprilate : 0.0125 mg/ml		1703
	Famotidine : 0.2 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Famotidine : 0.2 mg/ml Epinephrine hydrochloride : 4 µg/ml		398
	Famotidine Erythromycin lactobionate : 2 mg/ml		397
	Famotidine : 0.2 mg/ml Esmolol hydrochloride : 10 mg/ml		398
	Famotidine : 2 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Famotidine : 2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Famotidine : 2 mg/ml Filgrastim : 30 µg/ml		244
	Famotidine : 2 mg/ml Fluconazole : 2 mg/ml		215
	Famotidine : 10 mg/ml Fluconazole : 2 mg/ml		496
	Famotidine : 2 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Famotidine : 0,08 mg/ml Flumazenil : 0,02 mg/ml		187
	Famotidine : 4 mg/ml Fosfomycin : 30 mg/ml		4055
	Famotidine : 4 mg/ml Fosfomycin : 30 mg/ml		4055
	Famotidine Furosemide : 10 mg/ml		397
	Famotidine : 2 mg/ml Furosemide : 3 mg/ml		215

	Famotidine : 0.2 mg/ml Furosemide : 0.8 mg/ml		398
	Famotidine : 2 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Famotidine : 2 mg/ml Gentamicin sulfate : 5 mg/ml		215
	Famotidine Gentamicin sulfate : 0,8 mg/ml		397
	Famotidine : 2 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Famotidine : 0.267 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403
	Famotidine : 2 mg/ml Haloperidol lactate : 0.2 mg/ml		215
	Famotidine Heparin sodium : 40 UI/ml		397
	Famotidine : 2 mg/ml Heparin sodium : 40 UI/ml		215
	Famotidine : 0.2 mg/ml Heparin sodium : 50 UI/ml		398
	Famotidine : 2 mg/ml Hetastarch : 60 mg/ml		1721
	Famotidine		215
	Famotidine : 0.02 mg/ml		394
	Famotidine : 2 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		215
	Famotidine : 2 mg/ml Hydroxyzine dihydrochloride : 4 mg/ml		215
	Famotidine Imipenem - cilastatin sodium : 10 mg/ml		397
	Famotidine : 0,25 mg/ml		4507
	Famotidine : 2,5 mg/ml		4507
	Famotidine : 0.017 & 0.033 mg/ml		522
	Famotidine : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
	Famotidine : 0.02 & 0.04 mg/ml		356
	Famotidine : 2 mg/ml		301
	Famotidine : 2 mg/ml		1415
	Famotidine : 0.2 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		398
	Famotidine Hydrocortisone sodium succinate : 125 mg/ml		397
	Famotidine : 2 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		215
	Famotidine : 4 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
	Famotidine : 4 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433

	Famotidine : 0.2 mg/ml Insulin : 0.03 UI/ml		398
	Famotidine : 4 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Famotidine : 4 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Famotidine : 0.2 mg/ml Isoprenaline hydrochloride : 0.004 mg/ml		398
	Famotidine : 0.2 mg/ml Labetalol hydrochloride : 1 mg/ml		398
	Famotidine : 0.2 mg/ml Lidocaine hydrochloride : 4 mg/ml		398
	Famotidine : 0.02 mg/ml		687
	Famotidine Lidocaine hydrochloride : 1 mg/ml		397
	Famotidine : 0.2 mg/ml Methylprednisolone sodium succinate : 1 mg/ml		398
	Famotidine Methylprednisolone sodium succinate : 40 mg/ml		397
	Famotidine : 2 mg/ml Metoclopramide hydrochloride : 5 mg/ml		215
	Famotidine Metoclopramide hydrochloride : 5 mg/ml		397
	Famotidine : 2 mg/ml Midazolam hydrochloride : 1.5 mg/ml		215
	Famotidine : 0.2 mg/ml Morphine sulfate : 1 mg/ml		62
	Famotidine : 0.02 & 0.04 mg/ml		354
	Famotidine : 0.02 & 0.05 mg/ml		355
	Famotidine : 2 mg/ml Linezolid : 2 mg/ml		1925
	Famotidine : 2 mg/ml Lorazepam : 0.1 mg/ml		215
	Famotidine : 2 mg/ml Magnesium sulfate : 100 mg/ml		215
	Famotidine Magnesium sulfate : 100 mg/ml		397
	Famotidine : 2 mg/ml Melphalan : 0.1 mg/ml		169
	Famotidine : 0.2 mg/ml Midazolam hydrochloride : 0.15 mg/ml		398
	Famotidine : 0.2 mg/ml Morphine sulfate : 0.2 mg/ml		398
	Famotidine Nafcillin sodium : 15 mg/ml		397
	Famotidine : 0.2 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
	Famotidine : 0.2 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
	Famotidine : 0.2 mg/ml Nitroglycerin : 0.8 mg/ml		398

	Famotidine Nitroglycerin : 0,085 mg/ml		397
	Famotidine : 0.2 mg/ml Nitroprusside sodium : 0.2 mg/ml		398
	Famotidine : 0.2 mg/ml Norepinephrine bitartrate : 0.004 mg/ml		398
	Famotidine : 2 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Famotidine : 0.2 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
	Famotidine Oxacillin sodium : 20 mg/ml		397
	Famotidine : 2 mg/ml Oxaliplatin : 0,5 mg/ml		1662
	Famotidine : 2 mg/ml Paclitaxel : 1.2 mg/ml		248
	Famotidine : 2 mg/ml Palonosetron hydrochloride : 50 µg/ml		2279
	Famotidine : 10 mg/ml Paracetamol : 10 mg/ml		4742
	Famotidine		215
	Famotidine : 2 mg/ml Pemetrexed disodium : 20 mg/ml		1953
	Famotidine : 2 mg/ml Pethidine hydrochloride : 4 mg/ml		215
	Famotidine : 0.2 mg/ml Pethidine hydrochloride : 10 mg/ml		62
	Famotidine : 0.2 mg/ml Phenylephrine hydrochloride : 0.02 mg/ml		398
	Famotidine Phenytoin sodium : 50 mg/ml		397
	Famotidine Phytomenadione : 2 mg/ml		397
	Famotidine : 2 mg/ml Piperacillin sodium : 40 mg/ml		215
	Famotidine Piperacillin sodium : 40 mg/ml		397
	Famotidine : 2 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
	Famotidine : 4 mg/ml Plazomicin sulfate : 24 mg/ml		4145
	Famotidine Posaconazole		4380
	Famotidine : 0.2 mg/ml Potassium chloride : 40 mEq/l		398
	Famotidine : 2 mg/ml Potassium chloride : 13.4 mEq/l		215
	Famotidine : 0.2 mg/ml Procainamide hydrochloride : 5 mg/ml		398
	Famotidine : 0.04 mg/ml Propofol		660

	Famotidine : 2 mg/ml Propofol : 10 mg/ml	Ø	300
	Famotidine : 2 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml	▲	59
	Famotidine Rocuronium bromide		3564
	Famotidine : 2 mg/ml Sargramostim : 10 µg/ml	▲	335
	Famotidine : 0.2 mg/ml Sodium bicarbonate : 84 mg/ml	◆	398
	Famotidine : 4 mg/ml Sulbactam/durlobactam : 15/15 mg/ml	▲	4801
	Famotidine : 4 mg/ml Tedizolid phosphate : 0.8 mg/ml	▲	3827
	Famotidine : 2 mg/ml Telavancin hydrochloride : 7.5 mg/ml	▲	3254
	Famotidine : 2 mg/ml Telavancin hydrochloride : 7.5 mg/ml	◆	3254
	Famotidine : 2 mg/ml Teniposide : 0.1 mg/ml	◆	905
	Famotidine : 0.2 mg/ml Theophylline : 1.6 mg/ml	◆	398
	Famotidine Thiamine hydrochloride : 100 mg/ml	◆	397
	Famotidine : 2 mg/ml Thiotepa : 1 mg/ml	◆	249
	Famotidine Ticarcillin / clavulanic acid : 31 mg/ml	◆	397
	Famotidine : 0.2 & 4 mg/ml Tirofiban : 50 µg/ml	◆	1420
	Famotidine : 0.2 & 4 mg/ml Tirofiban : 50 µg/ml	▲	1420
	Famotidine Tirofiban		1512
	Famotidine : 0,2 mg/ml Vancomycin hydrochloride : 5 mg/ml	◆	1748
	Famotidine : 0.2 mg/ml Verapamil hydrochloride : 0.1 mg/ml	◆	398
	Famotidine : 2 mg/ml Vinorelbine tartrate : 1 mg/ml	▲	84



Voie d'administration





Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
77	Revue	Shea BF, Souney PF. Stability of famotidine frozen in polypropylene syringes. Am J Hosp Pharm 1990 ; 47: 2073-2074.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
187	Revue	Olsen KM, Gurley BJ, Davis GA, Christensen R, Monaghan MS. Stability of flumazenil with selected drugs in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 1907-1912.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
237	Revue	Lee DKT, Wong CY, Wang DP, Chang LC, Wu KH. Stability of cefmetazole and famotidine. Am J Health-Syst Pharm 1996 ; 53: 432.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.

251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
354	Revue	Montoro JB, Pou L, Salvador P, Pastor C, Cano SM. Stability of famotidine 20 and 40 mg/L in total nutrient admixtures. Am J Hosp Pharm 1989 ; 46: 2329-2332.
355	Revue	Bullock L, Fitzgerald JF, Glick MR. Stability of famotidine 20 and 50 mg/L in total nutrient admixtures. Am J Hosp Pharm 1989 ; 46: 2326-2329.
356	Revue	Bullock LS, Fitzgerald JF, Glick MR, Parks RB, Schnabel JG, Hancock BG. Stability of famotidine 20 and 40 mg/L and amino acids in total parenteral nutrient solutions. Am J Hosp Pharm 1989 ; 46: 2321-2325.
394	Revue	DiStefano JE, Mitrano FP, Baptista RJ, Der MM, Silvestri Ap, Palombo JD, Bistran BR. Long-term stability of famotidine 20 mg/L in a total parenteral nutrient solution. Am J Hosp Pharm 1989 ; 46: 2333-2335.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
403	Revue	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.

522	Revue	Walker SE, Iazetta J, Lau DWC, Madorin PL. Famotidine stability in total parenteral nutrient solutions. Can J Hosp Pharm 1989 ; 42: 97-103.
553	Revue	Bullock LS, Fitzgerald JF, Glick MR. Stability of famotidine in minibags refrigerated and/or frozen. Ann Pharmacotherapy 1989 ; 23: 132-135.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
687	Revue	Shea BF, Souney PF. Stability of famotidine in a 3-in-1 total nutrient admixture. Ann Pharmacotherapy 1990 ; 24: 232-235.
690	Revue	Bullock LS, Fitzgerald JF, Mazur HL. Stability of intravenous famotidine stored in polyvinyl chloride syringes. Ann Pharmacotherapy 1989 ; 23: 588-590.
693	Revue	Das Gupta V, Parasrampur J, Bethea C. Chemical stabilities of famotidine and ranitidine hydrochloride in intravenous admixtures. J Clin Pharm Ther 1988 ; 13: 329-334.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1420	Revue	Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther 1999 ; 24: 125-132.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1512	Laboratoire	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015

1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1703	Revue	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1748	Revue	Wang DP, Wang MT, Wong CY, Lee DKT. Compatibility of vancomycin hydrochloride and famotidine in 5% dextrose injection. Int J Pharm Compound 1997 ; 1: 354-355.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2166	Revue	Nassr S, Dubuc MC, Lavoie P, Brazier JL. HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine. J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmore T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.


2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocartil with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2279	Revue	Kupiec T, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 18: 1735-1759.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3539	Laboratoire	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3564	Laboratoire	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4507	Revue	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61

4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Stabilis



Famotidine



Stabilité des préparations

240 mg ®=? (Merck Sharp & Dohme)		Eau distillée Sirop de cerise >> 30 ml	24°C		15			2516
240 mg ®=? (Merck Sharp & Dohme)		Eau distillée Sirop de cerise >> 30 ml	4°C		20			2516
		2800 mg Pepcid® Eau ppi >> paste OraPlus® 175 ml Orasweet ® 175 ml	23-25°C		95			2392



Bibliographie

	Type	Source
2392	Revue	Dentinger PJ, Swenson CF, Anaizi NH. Stability of famotidine in an extemporaneously compounded oral liquid Am J Health-Syst Pharm 2000 ; 57: 1340-1342.
2516	Revue	Quercia RA, Jay GT, Fan C. Stability of famotidine in an extemporaneously prepared oral liquid. Am J Hosp Pharm 1993 ; 50: 691-693.



Dictionnaire

	Antihistaminique H2		injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	Eau pour préparation injectable		A l'abri de la lumière
	Jour		Chlorure de sodium 0,9%
	Avec ou sans lumière		Non précisée
	Glucose 5%		Seringue polypropylène
	Stabilité en mélange		Solvant
	Molécule		Verre
	Lumière		Heure
	Non précisé		Compatibilités
	Compatible		Précipitation immédiate
	Incompatible		Incompatibilité non précisée
	RL Ringer lactate		NaCl 0,9% + bactériostatique
	Solvant spécifique		Nutrition parentérale (mélange binaire)
	Nutrition parentérale (mélange ternaire)		Aucun
	Instabilité de l'émulsion à 4 heures		Voie d'administration
	Intraveineuse		Perfusion intraveineuse
	Bibliographie		Solution buvable
	Stabilité des préparations		Origine
	Excipient		Comprimés
	Flacon plastique		Dictionnaire